A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai East Hospital
With
Nanjing Legend Biotech Co.
East Clinical Center of Oncology
Anhui Provincial Hospital
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. The subjects have been fully informed of the possible risks and benefits of participating in this study and have voluntarily signed the informed consent form (ICF)
2. Age: 18-70 years (including 18 and 70 years)
3. Female subjects with histologically or cytologically confirmed advanced epithelial ovarian cancer including fallopian tube and primary peritoneal cancers
4. Mesothelin (MSLN) positive
5. Prior adequate standard of care, treatment failure or intolerance.
6. Imaging shows an evaluable tumor lesion
7. ECOG 0-1
8. Expected survival ≥ 3 months
You may not be if
1. Patients who have received the following anti-tumor treatments prior to apheresis:
* Cytotoxic therapy within 14 days
* Small molecule targeted therapy within 14 days or at least 5 half-lives, whichever is shorter
* Therapy with monoclonal antibody within 21 days
* Immunomodulatory therapy within 7 days
* Radiotherapy within 14 days and endocrine therapy within 14 days (including tamoxifen, aromatase inhibitor, high-potency progesterone and gonadotropin-releasing hormone analogue, etc.)
2. Previously treated with CAR-T/TCR-T cell therapy against any target or other cell therapies or therapeutic tumor vaccine
3. Previously treated with any MSLN-targeted therapy
4. Brain metastases with central nervous system symptoms
5. Pregnant or lactating women
6. Any condition in which, in the opinion of the investigator, the subject is ineligible for participation in the study
Clareo Health | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
